Illumina unveils upgraded genome sequence service
The IGS service uses Illumina’s HiSeq 2500 sequencing system, which is capable of completing a sequencing run on a whole human genome in one day. The service, which
The European Commission (EC) has granted orphan designation to Lundbeck’s investigational monoclonal antibody asedebart (Lu AG13909) for the treatment of Cushing’s syndrome of endogenous origin.
Pursuant to the agreement, screening and hit-to-lead chemistry will take place in the Broad’s Chemical Biology Platform and AstraZeneca will optimize, develop and commercialize potential compounds from identified,